2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Rutika J. Mehta, MD, MPH, discusses the current treatment paradigm in HER2-positive gastric cancer.
Rutika J. Mehta, MD, MPH, a medical oncologist specializing in gastrointestinal cancer at Moffitt Cancer Center, discusses the current treatment paradigm in HER2-positive gastric cancer.
Unlike the HER2-positive breast cancer space, patients with HER2-positive gastric cancer have limited treatment options, says Mehta.
Moreover, since there are no data supporting the continuation of trastuzumab (Herceptin) after disease progression, the field is working to identify the mechanism of resistance to trastuzumab, Mehta explains.
Additionally, HER2-positive gastric cancer tends to be more heterogeneous compared with HER2-positive breast cancer, which poses the question of whether lesion-specific biopsies are representative of the entire disease. As such, the optimal role of trastuzumab and other anti–HER2-based regimens remain largely unknown in this space, Mehta concludes.